Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30270544 | 0.80 | HDAC3 (0.41) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL24124848 | 0.80 | HDAC3 (0.41) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1257763 | 0.79 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL4313605 | 0.79 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL5913443 | 0.78 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL1548277 | 0.77 | GABRA1 (0.44) | TDP1 | |
| SCHEMBL961729 | 0.76 | PNMT (0.44) | TDP1 | |
| SCHEMBL12375147 | 0.73 | CYP3A4 (0.36) | TDP1 | |
| SCHEMBL633453 | 0.72 | CYP3A4 (0.40) | TDP1 | |
| SCHEMBL23369512 | 0.72 | CYP3A4 (0.35) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47122-E1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA University—Industry Collaboration Foundation (KR) | 2018-11-13 | — | — | US | disclosed |
| EP-2947081-B1 | 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-10-18 | — | — | EP | disclosed |
| EP-2588479-B3 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-03-29 | — | — | EP | disclosed |
| CN-103025731-B | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | EWHA UNIVERSITY INDUSTRY COLLABORATION FOUNDATION (KR) | 2016-01-13 | — | — | CN | disclosed |
| EP-2947081-A1 | 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors | Ewha University-Industry Collaboration Foundation (KR) | 2015-11-25 | — | — | EP | disclosed |
| EP-2588479-B1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | UNIV EWHA IND COLLABORATION (KR) | 2015-03-04 | — | — | EP | disclosed |
| EP-2588479-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | Ewha University-Industry Collaboration Foundation (KR) | 2013-05-08 | — | — | EP | disclosed |
| CN-103025731-A | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | UNIV EWHA IND COLLABORATION | 2013-04-03 | — | — | CN | disclosed |
| WO-2012002680-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-01-05 | — | — | WO | disclosed |
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-29 | — | — | US | disclosed |
| US-8080568-B1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | ALK, ACVR1, ACVRL1 | SLC6A4 1281/4885SLC6A2 2890/4885SLC6A3 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.